ClinicalTrials.gg
CompletedNCT02990338ICARIA-MMUpdated Jan 17, 2025Results posted

Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients

A Phase 3 interventional study of Isatuximab and Pomalidomide in Plasma Cell Myeloma, sponsored by Sanofi. Completed at 111 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-17.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
307
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing isatuximab in Multiple Myeloma — 15 open to participants now, 34 under way, 9 of them phase 3. isatuximab · Multiple Myeloma.

Enrollment
9th of 50
307 · median 55
Started
2016
with 1 other
Phase 3
9 of 50
1 open now
Registered
7th of 50
by date
Lead sponsor
13 of 50
Sanofi

Among the 50 studies testing isatuximab in Multiple Myeloma, this one is the 9th largest by enrollment, is one of 2 that started in 2016, is one of 9 in phase 3, and was the 7th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 50 studies testing isatuximab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About isatuximab

isatuximab: first FDA approval 2020 (SARCLISA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing isatuximab in Multiple Myeloma, or all of them as a file.
02

Study summary

Primary Objective:

To demonstrate the benefit of isatuximab in combination with pomalidomide and low-dose dexamethasone in the prolongation of Progression Free Survival (PFS) as compared to pomalidomide and low-dose dexamethasone in participants with refractory or relapsed and refractory multiple myeloma (MM).

Secondary Objectives:

  • To evaluate the Overall Response Rate (ORR) as per International Myeloma Working Group (IMWG) criteria in each arm.
  • To compare the Overall Survival (OS) between the two arms.
  • To evaluate the Time To Progression (TTP) in each arm.
  • To evaluate the PFS in high risk cytogenetic population in each arm.
  • To evaluate the Duration of Response (DOR) in each arm.
  • To evaluate the safety in both treatment arms.
  • To determine the Pharmacokinetic profile of isatuximab in combination with pomalidomide.
  • To evaluate the immunogenicity of isatuximab.
  • To assess disease-specific and generic health-related quality of life (HRQL), disease and treatment-related symptoms, health state utility, and health status.
Read the detailed description

The duration of the study for the participants included a period for screening of up to 21 days (or up to 28 days for women who can become pregnant). Participants continued study treatment until disease progression, unacceptable adverse reaction, participants' wish or other reason of discontinuation.

During follow-up, participants who discontinued the study treatment due to progression of the disease were followed every 3 months (12 weeks) for survival (or until cut-off date), and participants who discontinued the study treatment prior to documentation of disease progression were followed-up every 4 weeks until disease progression, and then every 3 months (12 weeks) for survival (or until cut-off date).

03

Conditions studied

  • Plasma Cell Myeloma

Browse trials for

Keywords

  • Anti-CD38 monoclonal antibody
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age superior or equal to 18 years or country's legal age of majority if the legal age was superior to 18 years old.
  • Participants had a documented diagnosis of multiple myeloma with evidence of i.e. serum M protein superior or equal to 0.5 grams per decilitre (g/dL) measured using serum protein immunoelectrophoresis and or urine M protein superior or equal to 200 mg per 24 hours measured using urine protein immunoelectrophoresis.
  • Participants had received at least 2 prior lines of anti-myeloma therapy, which must include at least 2 consecutive cycles of lenalidomide and a proteasome inhibitor (bortezomib, carfilzomib or ixazomib) given alone or in combination.
  • Participants had failed treatment with lenalidomide and a proteasome inhibitor (bortezomib, carfilzomib, or ixazomib) alone or in combination (Intolerant, progression within 6 months after reaching Partial Response or better).
  • Participants had progressed on or within 60 days after end of previous therapy before to study entry, i.e., to the last .

Exclusion criteria

Exclusion criteria:

  • Primary multiple myeloma defined as participants who had never achieved at least a minimal response (MR) with any treatment during the disease course.
  • Free Light Chain only.
  • Prior therapy with pomalidomide.
  • Any anti-myeloma drug treatment within 14 days before randomization, including dexamethasone.
  • performance status superior to 2.
  • inferior to 75 000 cells per microliter (mcL) if inferior to 50% of bone marrow (BM) nucleated cells are plasma cells, and inferior to 30 000 cells per mcL if superior or equal to 50% of BM nucleated cells are plasma cells. Platelet transfusion was not allowed within three days before the screening visit.
  • inferior to 1000 per mcL (1*10\^9/L).
  • inferior to 30 mL per minute (Modification of Diet in Renal Disease [] Formula).
  • Total superior to 2* (Upper Limit of Normal).
  • Corrected serum calcium superior to 14 milligrams per deciliter (mg/dL) (superior to 3.5 millimoles per liter (mmol/L).
  • (AST) and/or Alanine Aminotransferase (ALT) superior to 3*ULN.
  • to immunomodulatory drugs (IMiDs) (thalidomide or lenalidomide) defined as any hypersensitivity reaction leading to stop IMiDs within the 2 first cycles or toxicity, which does meet intolerance definition.
  • Hypersensitivity to dexamethasone, sucrose histidine (as base and hydrochloride salt), and polysorbate 80 or any of the components of study therapy that are not amenable to premedication with , or H2 blockers that would prohibit further treatment with these agents.
  • Significant cardiac dysfunction; myocardial infarction within 12 months; unstable, poorly controlled angina pectoris.
  • Pregnant or breastfeeding woman or female who intends to become pregnant during the participation in the study.
  • Male participants who disagreed to practice true abstinence or disagreed to use a condom during sexual contact with a pregnant female or a female of while participating in the study, during dose interruptions and at least 3 or 5 months following study treatment discontinuation, even if he had undergone a successful vasectomy.
  • All participants who disagreed to refrain from donating blood while on study treatment and for 4 weeks after discontinuation from this study treatment.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
307 participants (actual)

Study arms

  • Active comparator
    Pd (pomalidomide + dexamethasone)

    Participants received pomalidomide 4 milligrams (mg) Per os (PO) on Days 1 to 21 of each 28-day treatment cycle plus dexamethasone 40 mg (participants greater than or equal to (\>=) 75 years of age received 20 mg dexamethasone) PO on Days 1, 8, 15 and 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 306.6 weeks).

    Drug: Pomalidomide · Drug: Dexamethasone

  • Experimental
    IPd (isatuximab + pomalidomide + dexamethasone)

    Participants received isatuximab 10 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Days 1, 8, 15, and 22 at Cycle 1, and then on Days 1 and 15 of subsequent cycles plus pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle and dexamethasone 40 mg (participants \>= 75 years of age received 20 mg dexamethasone), PO or IV on Day 1, 8, 15, 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 311.0 weeks).

    Drug: Isatuximab · Drug: Pomalidomide · Drug: Dexamethasone

Interventions

  • Pharmaceutical form: solution for infusion Route of administration: intravenous

    Also known as: SAR650984, Sarclisa

  • Pharmaceutical form: capsule Route of administration: oral

    Also known as: POMALYST IMNOVID

  • Pharmaceutical form: tablets or solution for infusion Route of administration: oral or intravenous

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS:time from date of randomization to date of first documentation of progressive disease (PD) determined by Independent Response Committee (IRC) or date of death from any cause, whichever comes first. If progression or death was not observed, participant was censored at date of last progression-free tumor assessment prior to study cut-off date. Analysis was performed by Kaplan-Meier method. PD as per International Myeloma Working Group (IMWG) criteria was defined as increase of \>=25% from lowest confirmed value in any one of the following criteria: serum M-protein (the absolute increase must be \>=0.5gram(g)/dL), serum M-protein increase \>=1g/dL if lowest M component was \>=5g/dL; urine M-component (absolute increase must be \>=200mg/24hour), appearance of new lesion(s),\>=50% increase from nadir in sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of \>1 lesion, or \>=50% increase in the longest diameter of a previous lesion \>1 centimeter in short axis.

    Time frame: From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration: 76.7 weeks)

Secondary outcomes

  1. Overall Response Rate (ORR): Percentage of Participants With Disease Response as Per Independent Response Committee (IRC)

    ORR (IMWG criteria): percentage of participants with stringent complete response(sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) as best overall response, assessed by IRC. sCR:negative immunofixation on serum and urine,disappearance of any soft tissue plasmacytomas,\<5% plasma cells in bone marrow aspirates plus normal free light chain(FLC)ratio(0.26-1.65), absence of clonal cells in bone marrow biopsy.CR:negative immunofixation on serum and urine,disappearance of any soft tissue plasmacytomas,\<5% plasma cells in bone marrow aspirates.VGPR: serum and urine M-protein detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-protein plus urine M-protein level \<100mg/24h/,\>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma. PR: \>=50% reduction of serum M-protein and reduction in 24h urinary M-protein by \>=90%/\<200mg/24h,if present at baseline,\>=50% reduction in the size (SPD) of soft tissue plasmacytomas.

    Time frame: From the date of randomization to the date of first documentation of progression or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration 76.7 weeks)

  2. Percentage of Participants With Best Overall Response (BOR) as Per Independent Response Committee

    BOR:best sequential response from start of treatment until disease progression, death, initiation of further anti-myeloma treatment/data cut-off, whichever comes first. Ordering of evaluations from best to worse was: sCR,CR,VGPR,PR, minimal response (MR), stable disease (SD), PD, and not evaluable.CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas,\<5% plasma cells in bone marrow aspirates. sCR:CR as defined previously plus normal FLC ratio (0.26 to 1.65), absence of clonal cells in bone marrow biopsy. VGPR: serum and urine M-protein detectable by immunofixation,\>=90% reduction in serum M-protein plus urine M-protein level \<100mg/24h,\>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma. PR: \>=50% reduction of serum M-protein and reduction in 24h urinary M-protein by \>=90%/\<200mg/24h. MR:\>=25% but \<=49% reduction in serum M-protein and reduction in 24h urine M-protein by 50-89%. SD: Not meeting criteria for CR,VGPR,PR,MR/PD.

    Time frame: From the date of randomization until disease progression, or death, initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration 76.7 weeks)

  3. Percentage of Participants With Very Good Partial Response (VGPR) or Better as Per Independent Response Committee

    VGPR rate was defined as the percentage of participants achieving a VGPR or better as BOR. VGPR was defined as serum and urine M-protein detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum M-protein plus urine M-protein level \<100 mg/24 h or \>=90% decrease in the sum of maximal perpendicular diameter compared to baseline in soft tissue plasmacytoma. BOR was defined as the best sequential response, using the IRC's assessment of response, from the start of treatment until disease progression (provided that the progression is subsequently confirmed in case of progression requiring confirmation), death, initiation of further anti-myeloma treatment, or cut-off date, whichever occurs first. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas,\<5% plasma cells in bone marrow aspirates.

    Time frame: From the date of randomization to the date of first documentation of progression, death, initiation of further anti-myeloma treatment, or data cut-off whichever comes first (maximum duration 76.7 weeks)

  4. Clinical Benefit Rate (CBR): Percentage of Participants With Clinical Benefit as Per Independent Response Committee

    CBR was defined as the percentage of participants achieving a MR or better as BOR. MR was defined as \>= 25% but \<= 49% reduction in serum M-protein and reduction in 24h urine M-protein by 50-89%, which still exceed 200 mg/24h; if present at baseline, \>=50% reduction in size (SPD) of soft tissue plasmacytomas was also required. BOR was defined as the best sequential response, using the IRC's assessment of response, from the start of treatment until disease progression (provided that the progression is subsequently confirmed in case of progression requiring confirmation), death, initiation of further anti-myeloma treatment, or cut-off date, whichever occurs first.

    Time frame: From the date of randomization to the date of first documentation of progression, death, initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration 76.7 weeks)

  5. Overall Survival (OS): Final Analysis

    OS was defined as the time from the date of randomization to death from any cause. In the absence of confirmation of death, survival time was censored at the last date participant was known to be alive or at the cut-off date, whichever comes first. This pre-specified final analysis was performed when the 220 OS events were met.

    Time frame: From the date of randomization to date of death from any cause or data cut-off date, whichever was earlier (maximum duration 245.6 weeks)

  6. Time to Progression (TTP) as Per Independent Response Committee

    TTP was defined as time from randomization to the date of first documentation of PD, as determined by the IRC. As per IMWG criteria, PD was defined for participants with increase of \>= 25% from lowest confirmed value in any one of the following criteria: serum M-protein (the absolute increase must be \>= 0.5 g/dL), serum M-protein increase \>=1 g/dL if the lowest M component was \>=5 g/dL; urine M-component (the absolute increase must be \>=200 mg/24hour), appearance of new lesion(s), \>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in the longest diameter of a previous lesion \>1 centimeter in short axis.

    Time frame: From the date of randomization to the date of first documentation of progression, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration 76.7 weeks)

  7. Progression Free Survival in High Risk Cytogenetic Population

    PFS in high risk cytogenetic population was defined as PFS in subgroup of participants carrying high risk cytogenetic changes including del(17p), translocation (t)(4;14) or translocation t(14;16) assessed by fluorescence in situ hybridization (FISH). PFS was defined as the time from date of randomization to date of first documentation of PD (determined by IRC) or date of death from any cause, whichever comes first. PD defined as per IMWG criteria as: increase of \>=25% from lowest confirmed value in any one of following criteria: serum M-protein (absolute increase must be \>=0.5 g/dL), serum M-protein increase \>=1 g/dL if lowest M component was \>=5 g/dL; urine M-component (absolute increase must be \>=200 mg/24hour), appearance of new lesion(s), \>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in the longest diameter of previous lesion \>1 centimeter (cm) in short axis.

    Time frame: From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration 76.7 weeks)

  8. Duration of Response (DOR) as Per Independent Response Committee

    DOR:time from date of first IRC determined response(PR or better) to date of first IRC-PD or death, whichever occurred first.DOR was determined only for participants who had achieved a response of PR or better based on disease assessment by IRC.If progression or death was not observed,participant was censored at date of participants last progression-free tumor assessment prior to initiation of further anti-myeloma treatment(if any)and study cut-off date. PD(IMWG criteria):increase of \>=25% from lowest confirmed value in any one of following criteria: serum M-protein (absolute increase must be \>=0.5 g/dL), serum M-protein increase \>=1g/dL if lowest M component was \>=5g/dL;urine M-component (absolute increase must be \>=200mg/24 hour),appearance of new lesion(s), \>=50% increase from nadir in SPD of \>1 lesion,or \>=50% increase in the longest diameter of a previous lesion \>1 cm in short axis. PR:\>=50% reduction of serum M-protein and reduction in 24h urinary M-protein by \>=90%/\<200mg/24h.

    Time frame: From the date of the first IRC determined response to the date of first IRC progression or death, whichever occurred first (maximum duration 76.7 weeks)

  9. Time to First Response (TT1R) as Per Independent Response Committee

    TT1R was defined as the time from randomization to the date of first IRC determined response (PR or better) that is subsequently confirmed. PR was defined as \>=50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \>=90% or to \<200 mg/24 h. In addition to the above listed criteria, if present at baseline, a \>=50% reduction in the size (SPD) of soft tissue plasmacytomas was also required.

    Time frame: From the date of randomization to the date of first IRC determined response, or death or data cut-off whichever comes first (maximum duration 76.7 weeks)

  10. Time to Best Response (TTBR) as Per Independent Response Committee

    TTBR was defined as the time from randomization to the date of first occurrence of IRC determined BOR (PR or better) that was subsequently confirmed. PR was defined as \>=50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \>=90% or to \<200 mg/24 h. In addition to the above listed criteria, if present at baseline, a \>=50% reduction in the size (SPD) of soft tissue plasmacytomas was also required. BOR was defined as the best sequential response, using the IRC's assessment of response, from the start of treatment until disease progression (provided that the progression is subsequently confirmed in case of progression requiring confirmation), death, initiation of further anti-myeloma treatment, or cut-off date, whichever occurs first.

    Time frame: From the date of randomization to date of first occurrence of IRC determined best overall response or data cut-off whichever comes first (maximum duration 76.7 weeks)

  11. Number of Participants With Minimal Residual Disease (MRD)

    MRD was assessed by next-generation sequencing in bone marrow samples from participants who achieved CR, to determine the depth of response at the molecular level. IMWG criteria for CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% plasma cells in bone marrow aspirates. MRD was classified as positive or negative at the minimum sensitivity of 1 in 10\^5 nucleated cells. MRD negativity was defined as the absence of the dominant clonotype sequence(s) identified in the bone marrow aspirate collected at screening. MRD positivity was defined as the presence of the dominant clonotype sequence(s) identified in the bone marrow aspirate collected at screening.

    Time frame: Up to 76.7 weeks

  12. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Adverse Event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the treatment. TEAEs were defined as AEs that developed, worsened (according to the Investigator opinion), or became serious during the treatment period (time from the first dose of study treatments up to 30 days after last dose of study treatments). An SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a medically important event.

    Time frame: From randomization up to 30 days after last dose of study drug (maximum duration up to 241.6 weeks for Pd arm and 245.6 weeks for IPd arm)

  13. Pharmacokinetics (PK) Parameter: Plasma Concentration of Isatuximab at End of Infusion (CEOI)

    CEOI was defined as the plasma concentration at end of infusion.

    Time frame: End of infusion on Cycle(C)1 Day(D)1 and Cycle1 Day 15; Cycle 2 Day 1; and Cycle 4 Day 1

  14. Pharmacokinetic Parameter: Accumulation Ratio of Isatuximab at Concentration at the End of Infusion (CEOI)

    Accumulation Ratio was defined as the ratio of CEOI of Cycle 2 Day 1 versus Cycle 1 Day 1 and Cycle 4 Day 1 versus Cycle 1 Day 1, where CEOI was the plasma concentration at the end of infusion.

    Time frame: End of infusion on Cycle 1 Day 1, Cycle 2 Day 1, and Cycle 4 Day 1

  15. Pharmacokinetic Parameter: Plasma Concentration of Isatuximab at 1 Hour After End of Infusion (CEOI+1 Hour)

    CEOI+1 hour was defined as the plasma concentration of isatuximab at 1 hour after end of infusion.

    Time frame: Cycle 1:1 hour after End of Infusion on Day 1; Cycle 4:1 hour after End of Infusion on Day 1

  16. PK Parameter: Plasma Concentration of Isatuximab at Ctrough

    Trough Concentration (Ctrough) is the concentration prior to study drug administration.

    Time frame: Pre-infusion on C1D1, C1D8, C1D15, C1D22, C2D1, C2D15, C3D1, C3D15, C4D1, C4D15, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1, C15D1, C16D1, C17D1, C18D1, C19D1, C20D1; End of treatment (EOT [30 days after last drug administration])

  17. PK Parameter: Accumulation Ratio of Isatuximab at Trough Concentration (Ctrough)

    Accumulation Ratio was defined as the ratio of Ctrough of Cycle 2 Day 1 versus Cycle 1 Day 8 and Cycle 4 Day 1 versus Cycle 1 Day 8, where Ctrough is the concentration prior to study drug administration.

    Time frame: Pre-infusion on Cycle 1 Day 8, Cycle 2 Day 1, and Cycle 4 Day 1

  18. Number of Participants With Anti-drug Antibodies (ADA)

    ADA were categorized as: pre-existing, treatment induced and treatment boosted response. Pre-existing ADA was defined as ADA that were present in samples drawn during the pretreatment period (i.e., before the first isatuximab administration). Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without preexisting ADA, including participants without pretreatment samples. Treatment boosted ADA was defined as pre-existing ADA that increased at least 2 titer steps between pre-treatment and post-treatment.

    Time frame: From randomization up to 60 days after last dose of study drug (maximum duration 76.7 weeks)

  19. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 30 Items (EORTC QLQ-C30): Global Health Status (GHS)/Quality of Life (QOL) Score

    EORTC-Quality of Life Questionnaire (QLQ)-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. EORTC QLQ-C30 included GHS/ QOL, functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant.

    Time frame: Baseline, Day 1 of each cycle (Cycle 3, Cycle 6, Cycle 9, and Cycle 17)

  20. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Multiple Myeloma Specific Module With 20 Items (EORTC QLQ-MY20): Disease Symptoms Domain Score

    EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. Disease symptoms domain is one of the four domain scores. Disease symptoms domain score used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0 -100 scale, where higher scores = more symptoms and lower health-related quality of life (HRQL) and lower score = less symptoms and more HRQL

    Time frame: Baseline, Day 1 of each cycle (Cycle 3, Cycle 6, Cycle 9, and Cycle 17)

  21. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Multiple Myeloma Specific Module With 20 Items (EORTC QLQ-MY20): Side Effects of Treatment Domain Score

    EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. Side effects of treatment domain is one of the four domain scores. Side effects of treatment domain score used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale, where higher scores = more side effects and lower HRQL and lower scores = less side effects and better HRQL.

    Time frame: Baseline, Day 1 of each cycle (Cycle 3, Cycle 6, Cycle 9, and Cycle 17)

  22. Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions (5D), 5 Levels (5L) (EQ-5D-5L) Score: Health State Utility Index Value

    The EQ-5D-5L is a standardized measure of health status that provides a general assessment of health and wellbeing. The EQ-5D descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has a 5-level response: no problems, slight problems, moderate problems, severe problems, and extreme problems. Response options are measured with a 5-point Likert scale (for the 5L version). The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state and lower score indicate worse health state.

    Time frame: Baseline, Day 1 of each cycle (Cycle 3, Cycle 6, Cycle 9, and Cycle 17)

  23. Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Score: Visual Analogic Scale (VAS)

    EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state utility index (descriptive system) and the EQ-5D-5L Visual Analog Scale. The Visual Analogue Scale is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.

    Time frame: Baseline, Day 1 of each cycle (Cycle 3, Cycle 6, Cycle 9, and Cycle 17)

07

Results

Posted Dec 6, 2019

Participant flow

The study was conducted at 102 sites in 24 countries. A total of 387 participants were screened between 22 December 2016 and 01 February 2018. Out of which, 307 participants were randomized in 1:1 ratio to IPd (Isatuximab + Pomalidomide + Dexamethasone) and Pd (Pomalidomide + Dexamethasone) arms using an interactive response technology (IRT).

Participant flow — Overall Study
MilestonePd (Pomalidomide + Dexamethasone)IPd (Isatuximab + Pomalidomide + Dexamethasone)
Started153154
Treated149152
Completed00
Not completed153154
Withdrew: Randomized and not treated42
Withdrew: Adverse event2322
Withdrew: Progressive disease118107
Withdrew: Poor compliance to protocol01
Withdrew: Withdrawal by subject68
Withdrew: Physician's decision26
Withdrew: Treatment extension study06
Withdrew: Unconfirmed disease progression per investigator01
Withdrew: Continue with therapy available commercially01

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS:time from date of randomization to date of first documentation of progressive disease (PD) determined by Independent Response Committee (IRC) or date of death from any cause, whichever comes first. If progression or death was not observed, participant was censored at date of last progression-free tumor assessment prior to study cut-off date. Analysis was performed by Kaplan-Meier method. PD as per International Myeloma Working Group (IMWG) criteria was defined as increase of \>=25% from lowest confirmed value in any one of the following criteria: serum M-protein (the absolute increase must be \>=0.5gram(g)/dL), serum M-protein increase \>=1g/dL if lowest M component was \>=5g/dL; urine M-component (absolute increase must be \>=200mg/24hour), appearance of new lesion(s),\>=50% increase from nadir in sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of \>1 lesion, or \>=50% increase in the longest diameter of a previous lesion \>1 centimeter in short axis.

Time frame:
From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration: 76.7 weeks)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsPd (Pomalidomide + Dexamethasone)IPd (Isatuximab + Pomalidomide + Dexamethasone)
Progression Free Survival (PFS)6.47 (4.468 to 8.279)11.53 (8.936 to 13.897)
Statistical analysis
  • Pd (Pomalidomide + Dexamethasone) vs IPd (Isatuximab + Pomalidomide + Dexamethasone) · Log Rank · p = 0.0005 (One-sided p-value based on Stratified log-rank test. Threshold for statistical significance at 0.025.) · Hazard ratio (hr): 0.596 · 95% CI 0.436 to 0.814Stratification was based on age (\<75 years versus \>=75 years) and number of previous lines of therapy (2 or 3 versus \>3) according to IRT.
SecondaryOverall Response Rate (ORR): Percentage of Participants With Disease Response as Per Independent Response Committee (IRC)

ORR (IMWG criteria): percentage of participants with stringent complete response(sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) as best overall response, assessed by IRC. sCR:negative immunofixation on serum and urine,disappearance of any soft tissue plasmacytomas,\<5% plasma cells in bone marrow aspirates plus normal free light chain(FLC)ratio(0.26-1.65), absence of clonal cells in bone marrow biopsy.CR:negative immunofixation on serum and urine,disappearance of any soft tissue plasmacytomas,\<5% plasma cells in bone marrow aspirates.VGPR: serum and urine M-protein detectable by immunofixation, not on electrophoresis/,\>=90% reduction in serum M-protein plus urine M-protein level \<100mg/24h/,\>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma. PR: \>=50% reduction of serum M-protein and reduction in 24h urinary M-protein by \>=90%/\<200mg/24h,if present at baseline,\>=50% reduction in the size (SPD) of soft tissue plasmacytomas.

Time frame:
From the date of randomization to the date of first documentation of progression or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration 76.7 weeks)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR): Percentage of Participants With Disease Response as Per Independent Response Committee (IRC)
percentage of participantsPd (Pomalidomide + Dexamethasone)IPd (Isatuximab + Pomalidomide + Dexamethasone)
Overall Response Rate (ORR): Percentage of Participants With Disease Response as Per Independent Response Committee (IRC)35.360.4
Statistical analysis
  • Pd (Pomalidomide + Dexamethasone) vs IPd (Isatuximab + Pomalidomide + Dexamethasone) · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for statistical significance at 0.025.)One sided p-value was stratified based on age (\<75 years versus \>=75 years) and number of previous lines (2 or 3 versus \>3) according to IRT.
SecondaryPercentage of Participants With Best Overall Response (BOR) as Per Independent Response Committee

BOR:best sequential response from start of treatment until disease progression, death, initiation of further anti-myeloma treatment/data cut-off, whichever comes first. Ordering of evaluations from best to worse was: sCR,CR,VGPR,PR, minimal response (MR), stable disease (SD), PD, and not evaluable.CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas,\<5% plasma cells in bone marrow aspirates. sCR:CR as defined previously plus normal FLC ratio (0.26 to 1.65), absence of clonal cells in bone marrow biopsy. VGPR: serum and urine M-protein detectable by immunofixation,\>=90% reduction in serum M-protein plus urine M-protein level \<100mg/24h,\>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma. PR: \>=50% reduction of serum M-protein and reduction in 24h urinary M-protein by \>=90%/\<200mg/24h. MR:\>=25% but \<=49% reduction in serum M-protein and reduction in 24h urine M-protein by 50-89%. SD: Not meeting criteria for CR,VGPR,PR,MR/PD.

Time frame:
From the date of randomization until disease progression, or death, initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration 76.7 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Best Overall Response (BOR) as Per Independent Response Committee
percentage of participantsPd (Pomalidomide + Dexamethasone)IPd (Isatuximab + Pomalidomide + Dexamethasone)
Stringent complete response0.70
Complete response1.34.5
Very good partial response6.527.3
Partial response26.828.6
Minimal response11.16.5
Stable disease29.421.4
Progressive Disease9.23.9
Not evaluable10.54.5
SecondaryPercentage of Participants With Very Good Partial Response (VGPR) or Better as Per Independent Response Committee

VGPR rate was defined as the percentage of participants achieving a VGPR or better as BOR. VGPR was defined as serum and urine M-protein detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum M-protein plus urine M-protein level \<100 mg/24 h or \>=90% decrease in the sum of maximal perpendicular diameter compared to baseline in soft tissue plasmacytoma. BOR was defined as the best sequential response, using the IRC's assessment of response, from the start of treatment until disease progression (provided that the progression is subsequently confirmed in case of progression requiring confirmation), death, initiation of further anti-myeloma treatment, or cut-off date, whichever occurs first. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas,\<5% plasma cells in bone marrow aspirates.

Time frame:
From the date of randomization to the date of first documentation of progression, death, initiation of further anti-myeloma treatment, or data cut-off whichever comes first (maximum duration 76.7 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Very Good Partial Response (VGPR) or Better as Per Independent Response Committee
percentage of participantsPd (Pomalidomide + Dexamethasone)IPd (Isatuximab + Pomalidomide + Dexamethasone)
Percentage of Participants With Very Good Partial Response (VGPR) or Better as Per Independent Response Committee8.531.8
SecondaryClinical Benefit Rate (CBR): Percentage of Participants With Clinical Benefit as Per Independent Response Committee

CBR was defined as the percentage of participants achieving a MR or better as BOR. MR was defined as \>= 25% but \<= 49% reduction in serum M-protein and reduction in 24h urine M-protein by 50-89%, which still exceed 200 mg/24h; if present at baseline, \>=50% reduction in size (SPD) of soft tissue plasmacytomas was also required. BOR was defined as the best sequential response, using the IRC's assessment of response, from the start of treatment until disease progression (provided that the progression is subsequently confirmed in case of progression requiring confirmation), death, initiation of further anti-myeloma treatment, or cut-off date, whichever occurs first.

Time frame:
From the date of randomization to the date of first documentation of progression, death, initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration 76.7 weeks)
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR): Percentage of Participants With Clinical Benefit as Per Independent Response Committee
percentage of participantsPd (Pomalidomide + Dexamethasone)IPd (Isatuximab + Pomalidomide + Dexamethasone)
Clinical Benefit Rate (CBR): Percentage of Participants With Clinical Benefit as Per Independent Response Committee46.466.9
SecondaryOverall Survival (OS): Final Analysis

OS was defined as the time from the date of randomization to death from any cause. In the absence of confirmation of death, survival time was censored at the last date participant was known to be alive or at the cut-off date, whichever comes first. This pre-specified final analysis was performed when the 220 OS events were met.

Time frame:
From the date of randomization to date of death from any cause or data cut-off date, whichever was earlier (maximum duration 245.6 weeks)
Reported as:
Median · months
Overall Survival (OS): Final Analysis
monthsPd (Pomalidomide + Dexamethasone)IPd (Isatuximab + Pomalidomide + Dexamethasone)
Overall Survival (OS): Final Analysis17.71 (14.390 to 26.218)24.57 (20.304 to 31.310)
Statistical analysis
  • Pd (Pomalidomide + Dexamethasone) vs IPd (Isatuximab + Pomalidomide + Dexamethasone) · Log Rank · p = 0.0319 (One-sided significance level was 0.02 using the O'Brien-Fleming alpha spending function.) · Hazard ratio (hr): 0.776 · 95% CI 0.594 to 1.015Stratified on age (\<75 years versus \>=75 years) and number of previous lines of therapy (2 or 3 versus \> 3) according to IRT.
SecondaryTime to Progression (TTP) as Per Independent Response Committee

TTP was defined as time from randomization to the date of first documentation of PD, as determined by the IRC. As per IMWG criteria, PD was defined for participants with increase of \>= 25% from lowest confirmed value in any one of the following criteria: serum M-protein (the absolute increase must be \>= 0.5 g/dL), serum M-protein increase \>=1 g/dL if the lowest M component was \>=5 g/dL; urine M-component (the absolute increase must be \>=200 mg/24hour), appearance of new lesion(s), \>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in the longest diameter of a previous lesion \>1 centimeter in short axis.

Time frame:
From the date of randomization to the date of first documentation of progression, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration 76.7 weeks)
Reported as:
Median · months
Time to Progression (TTP) as Per Independent Response Committee
monthsPd (Pomalidomide + Dexamethasone)IPd (Isatuximab + Pomalidomide + Dexamethasone)
Time to Progression (TTP) as Per Independent Response Committee7.75 (5.027 to 9.758)12.71 (11.203 to 15.211)
SecondaryProgression Free Survival in High Risk Cytogenetic Population

PFS in high risk cytogenetic population was defined as PFS in subgroup of participants carrying high risk cytogenetic changes including del(17p), translocation (t)(4;14) or translocation t(14;16) assessed by fluorescence in situ hybridization (FISH). PFS was defined as the time from date of randomization to date of first documentation of PD (determined by IRC) or date of death from any cause, whichever comes first. PD defined as per IMWG criteria as: increase of \>=25% from lowest confirmed value in any one of following criteria: serum M-protein (absolute increase must be \>=0.5 g/dL), serum M-protein increase \>=1 g/dL if lowest M component was \>=5 g/dL; urine M-component (absolute increase must be \>=200 mg/24hour), appearance of new lesion(s), \>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in the longest diameter of previous lesion \>1 centimeter (cm) in short axis.

Time frame:
From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration 76.7 weeks)
Reported as:
Median · months
Progression Free Survival in High Risk Cytogenetic Population
monthsPd (Pomalidomide + Dexamethasone)IPd (Isatuximab + Pomalidomide + Dexamethasone)
Progression Free Survival in High Risk Cytogenetic Population3.745 (2.793 to 7.885)7.491 (2.628 to NA)
SecondaryDuration of Response (DOR) as Per Independent Response Committee

DOR:time from date of first IRC determined response(PR or better) to date of first IRC-PD or death, whichever occurred first.DOR was determined only for participants who had achieved a response of PR or better based on disease assessment by IRC.If progression or death was not observed,participant was censored at date of participants last progression-free tumor assessment prior to initiation of further anti-myeloma treatment(if any)and study cut-off date. PD(IMWG criteria):increase of \>=25% from lowest confirmed value in any one of following criteria: serum M-protein (absolute increase must be \>=0.5 g/dL), serum M-protein increase \>=1g/dL if lowest M component was \>=5g/dL;urine M-component (absolute increase must be \>=200mg/24 hour),appearance of new lesion(s), \>=50% increase from nadir in SPD of \>1 lesion,or \>=50% increase in the longest diameter of a previous lesion \>1 cm in short axis. PR:\>=50% reduction of serum M-protein and reduction in 24h urinary M-protein by \>=90%/\<200mg/24h.

Time frame:
From the date of the first IRC determined response to the date of first IRC progression or death, whichever occurred first (maximum duration 76.7 weeks)
Reported as:
Median · months
Duration of Response (DOR) as Per Independent Response Committee
monthsPd (Pomalidomide + Dexamethasone)IPd (Isatuximab + Pomalidomide + Dexamethasone)
Duration of Response (DOR) as Per Independent Response Committee11.07 (8.542 to NA)13.27 (10.612 to NA)
SecondaryTime to First Response (TT1R) as Per Independent Response Committee

TT1R was defined as the time from randomization to the date of first IRC determined response (PR or better) that is subsequently confirmed. PR was defined as \>=50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \>=90% or to \<200 mg/24 h. In addition to the above listed criteria, if present at baseline, a \>=50% reduction in the size (SPD) of soft tissue plasmacytomas was also required.

Time frame:
From the date of randomization to the date of first IRC determined response, or death or data cut-off whichever comes first (maximum duration 76.7 weeks)
Reported as:
Median · months
Time to First Response (TT1R) as Per Independent Response Committee
monthsPd (Pomalidomide + Dexamethasone)IPd (Isatuximab + Pomalidomide + Dexamethasone)
Time to First Response (TT1R) as Per Independent Response Committee3.02 (2.825 to 5.060)1.94 (1.314 to 2.004)
SecondaryTime to Best Response (TTBR) as Per Independent Response Committee

TTBR was defined as the time from randomization to the date of first occurrence of IRC determined BOR (PR or better) that was subsequently confirmed. PR was defined as \>=50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \>=90% or to \<200 mg/24 h. In addition to the above listed criteria, if present at baseline, a \>=50% reduction in the size (SPD) of soft tissue plasmacytomas was also required. BOR was defined as the best sequential response, using the IRC's assessment of response, from the start of treatment until disease progression (provided that the progression is subsequently confirmed in case of progression requiring confirmation), death, initiation of further anti-myeloma treatment, or cut-off date, whichever occurs first.

Time frame:
From the date of randomization to date of first occurrence of IRC determined best overall response or data cut-off whichever comes first (maximum duration 76.7 weeks)
Reported as:
Median · months
Time to Best Response (TTBR) as Per Independent Response Committee
monthsPd (Pomalidomide + Dexamethasone)IPd (Isatuximab + Pomalidomide + Dexamethasone)
Time to Best Response (TTBR) as Per Independent Response Committee5.06 (3.778 to 7.885)4.30 (2.891 to 5.125)
SecondaryNumber of Participants With Minimal Residual Disease (MRD)

MRD was assessed by next-generation sequencing in bone marrow samples from participants who achieved CR, to determine the depth of response at the molecular level. IMWG criteria for CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% plasma cells in bone marrow aspirates. MRD was classified as positive or negative at the minimum sensitivity of 1 in 10\^5 nucleated cells. MRD negativity was defined as the absence of the dominant clonotype sequence(s) identified in the bone marrow aspirate collected at screening. MRD positivity was defined as the presence of the dominant clonotype sequence(s) identified in the bone marrow aspirate collected at screening.

Time frame:
Up to 76.7 weeks
Reported as:
Count of participants · Participants
Number of Participants With Minimal Residual Disease (MRD)
ParticipantsPd (Pomalidomide + Dexamethasone)IPd (Isatuximab + Pomalidomide + Dexamethasone)
MRD negative:1 in 10^4010
MRD negative:1 in 10^508
MRD negative:1 in 10^602
MRD positive:1 in 10^424
MRD positive:1 in 10^526
MRD positive:1 in 10^629
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Adverse Event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the treatment. TEAEs were defined as AEs that developed, worsened (according to the Investigator opinion), or became serious during the treatment period (time from the first dose of study treatments up to 30 days after last dose of study treatments). An SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a medically important event.

Time frame:
From randomization up to 30 days after last dose of study drug (maximum duration up to 241.6 weeks for Pd arm and 245.6 weeks for IPd arm)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsPd (Pomalidomide + Dexamethasone)IPd (Isatuximab + Pomalidomide + Dexamethasone)
Any TEAE146151
Any treatment emergent SAE91112
Any TEAE leading to treatment discontinuation2219
SecondaryPharmacokinetics (PK) Parameter: Plasma Concentration of Isatuximab at End of Infusion (CEOI)

CEOI was defined as the plasma concentration at end of infusion.

Time frame:
End of infusion on Cycle(C)1 Day(D)1 and Cycle1 Day 15; Cycle 2 Day 1; and Cycle 4 Day 1
Reported as:
Geometric mean · microgram per milliliter (mcg/mL)
Pharmacokinetics (PK) Parameter: Plasma Concentration of Isatuximab at End of Infusion (CEOI)
microgram per milliliter (mcg/mL)IPd (Isatuximab + Pomalidomide + Dexamethasone)
End of infusion: C1D1163.05 ± 34.528
End of infusion: C1D15269.20 ± 32.622
End of infusion: C2D1299.85 ± 35.921
End of infusion: C4D1279.31 ± 47.555
SecondaryPharmacokinetic Parameter: Accumulation Ratio of Isatuximab at Concentration at the End of Infusion (CEOI)

Accumulation Ratio was defined as the ratio of CEOI of Cycle 2 Day 1 versus Cycle 1 Day 1 and Cycle 4 Day 1 versus Cycle 1 Day 1, where CEOI was the plasma concentration at the end of infusion.

Time frame:
End of infusion on Cycle 1 Day 1, Cycle 2 Day 1, and Cycle 4 Day 1
Reported as:
Geometric mean · ratio
Pharmacokinetic Parameter: Accumulation Ratio of Isatuximab at Concentration at the End of Infusion (CEOI)
ratioIPd (Isatuximab + Pomalidomide + Dexamethasone)
C2D1 versus C1D11.860 ± 170.9185
C4D1 versus C1D11.777 ± 224.2542
SecondaryPharmacokinetic Parameter: Plasma Concentration of Isatuximab at 1 Hour After End of Infusion (CEOI+1 Hour)

CEOI+1 hour was defined as the plasma concentration of isatuximab at 1 hour after end of infusion.

Time frame:
Cycle 1:1 hour after End of Infusion on Day 1; Cycle 4:1 hour after End of Infusion on Day 1
Reported as:
Geometric mean · mcg/mL
Pharmacokinetic Parameter: Plasma Concentration of Isatuximab at 1 Hour After End of Infusion (CEOI+1 Hour)
mcg/mLIPd (Isatuximab + Pomalidomide + Dexamethasone)
C1D1171.55 ± 38.299
C4D1294.96 ± 57.331
SecondaryPK Parameter: Plasma Concentration of Isatuximab at Ctrough

Trough Concentration (Ctrough) is the concentration prior to study drug administration.

Time frame:
Pre-infusion on C1D1, C1D8, C1D15, C1D22, C2D1, C2D15, C3D1, C3D15, C4D1, C4D15, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1, C15D1, C16D1, C17D1, C18D1, C19D1, C20D1; End of treatment (EOT [30 days after last drug administration])
Reported as:
Geometric mean · mcg/mL
PK Parameter: Plasma Concentration of Isatuximab at Ctrough
mcg/mLIPd (Isatuximab + Pomalidomide + Dexamethasone)
C1D10.00 ± 1194.973
C1D831.49 ± 53.602
C1D1557.89 ± 54.764
C1D2284.82 ± 57.666
C2D189.09 ± 60.155
C2D1589.35 ± 61.167
C3D164.15 ± 76.469
C3D1591.73 ± 78.406
C4D186.05 ± 70.062
C4D15105.42 ± 68.035
C5D1106.08 ± 65.275
C6D1111.33 ± 64.985
C7D1134.14 ± 60.017
C8D1146.15 ± 55.946
C9D1162.84 ± 65.193
C10D1145.86 ± 60.719
C11D1169.39 ± 56.078
C12D1182.32 ± 56.814
C13D1215.85 ± 54.667
C14D1214.88 ± 55.172
C15D1253.61 ± 58.885
C16D1206.60 ± 50.965
C17D1242.79 ± 45.364
C18D1216.70 ± 58.273
C19D1240.36 ± 42.099
C20D1164.07
EOT9.51 ± 136.883
SecondaryPK Parameter: Accumulation Ratio of Isatuximab at Trough Concentration (Ctrough)

Accumulation Ratio was defined as the ratio of Ctrough of Cycle 2 Day 1 versus Cycle 1 Day 8 and Cycle 4 Day 1 versus Cycle 1 Day 8, where Ctrough is the concentration prior to study drug administration.

Time frame:
Pre-infusion on Cycle 1 Day 8, Cycle 2 Day 1, and Cycle 4 Day 1
Reported as:
Geometric mean · ratio
PK Parameter: Accumulation Ratio of Isatuximab at Trough Concentration (Ctrough)
ratioIPd (Isatuximab + Pomalidomide + Dexamethasone)
C2D1 versus C1D82.689 ± 734.5547
C4D1 versus C1D82.620 ± 645.4171
SecondaryNumber of Participants With Anti-drug Antibodies (ADA)

ADA were categorized as: pre-existing, treatment induced and treatment boosted response. Pre-existing ADA was defined as ADA that were present in samples drawn during the pretreatment period (i.e., before the first isatuximab administration). Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without preexisting ADA, including participants without pretreatment samples. Treatment boosted ADA was defined as pre-existing ADA that increased at least 2 titer steps between pre-treatment and post-treatment.

Time frame:
From randomization up to 60 days after last dose of study drug (maximum duration 76.7 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADA)
ParticipantsIPd (Isatuximab + Pomalidomide + Dexamethasone)
Pre-existing ADA0
Treatment induced ADA0
Treatment boosted ADA0
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 30 Items (EORTC QLQ-C30): Global Health Status (GHS)/Quality of Life (QOL) Score

EORTC-Quality of Life Questionnaire (QLQ)-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. EORTC QLQ-C30 included GHS/ QOL, functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant.

Time frame:
Baseline, Day 1 of each cycle (Cycle 3, Cycle 6, Cycle 9, and Cycle 17)
Reported as:
Mean · score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 30 Items (EORTC QLQ-C30): Global Health Status (GHS)/Quality of Life (QOL) Score
score on a scalePd (Pomalidomide + Dexamethasone)IPd (Isatuximab + Pomalidomide + Dexamethasone)
Baseline61.19 ± 20.6460.10 ± 20.02
Day 1: Cycle 3-1.45 ± 21.03-1.22 ± 22.42
Day 1: Cycle 6-0.12 ± 22.26-0.16 ± 18.28
Day 1: Cycle 91.06 ± 19.970.41 ± 20.99
Day 1: Cycle 17-9.17 ± 24.36-1.92 ± 19.29
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Multiple Myeloma Specific Module With 20 Items (EORTC QLQ-MY20): Disease Symptoms Domain Score

EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. Disease symptoms domain is one of the four domain scores. Disease symptoms domain score used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0 -100 scale, where higher scores = more symptoms and lower health-related quality of life (HRQL) and lower score = less symptoms and more HRQL

Time frame:
Baseline, Day 1 of each cycle (Cycle 3, Cycle 6, Cycle 9, and Cycle 17)
Reported as:
Mean · score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Multiple Myeloma Specific Module With 20 Items (EORTC QLQ-MY20): Disease Symptoms Domain Score
score on a scalePd (Pomalidomide + Dexamethasone)IPd (Isatuximab + Pomalidomide + Dexamethasone)
Baseline24.91 ± 20.6724.12 ± 20.54
Day 1: Cycle 3-3.79 ± 16.09-2.07 ± 17.51
Day 1: Cycle 6-4.08 ± 17.95-3.30 ± 16.01
Day 1: Cycle 9-2.83 ± 15.04-4.66 ± 13.73
Day 1: Cycle 17-3.33 ± 15.540.00 ± 21.40
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Multiple Myeloma Specific Module With 20 Items (EORTC QLQ-MY20): Side Effects of Treatment Domain Score

EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. Side effects of treatment domain is one of the four domain scores. Side effects of treatment domain score used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale, where higher scores = more side effects and lower HRQL and lower scores = less side effects and better HRQL.

Time frame:
Baseline, Day 1 of each cycle (Cycle 3, Cycle 6, Cycle 9, and Cycle 17)
Reported as:
Mean · score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Multiple Myeloma Specific Module With 20 Items (EORTC QLQ-MY20): Side Effects of Treatment Domain Score
score on a scalePd (Pomalidomide + Dexamethasone)IPd (Isatuximab + Pomalidomide + Dexamethasone)
Baseline17.49 ± 15.2515.60 ± 11.63
Day 1: Cycle 31.69 ± 11.542.61 ± 13.39
Day 1: Cycle 6-0.13 ± 15.102.11 ± 11.78
Day 1: Cycle 91.43 ± 14.663.14 ± 11.88
Day 1: Cycle 17-2.93 ± 15.943.02 ± 15.72
SecondaryChange From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions (5D), 5 Levels (5L) (EQ-5D-5L) Score: Health State Utility Index Value

The EQ-5D-5L is a standardized measure of health status that provides a general assessment of health and wellbeing. The EQ-5D descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has a 5-level response: no problems, slight problems, moderate problems, severe problems, and extreme problems. Response options are measured with a 5-point Likert scale (for the 5L version). The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state and lower score indicate worse health state.

Time frame:
Baseline, Day 1 of each cycle (Cycle 3, Cycle 6, Cycle 9, and Cycle 17)
Reported as:
Mean · score on a scale
Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions (5D), 5 Levels (5L) (EQ-5D-5L) Score: Health State Utility Index Value
score on a scalePd (Pomalidomide + Dexamethasone)IPd (Isatuximab + Pomalidomide + Dexamethasone)
Baseline0.70 ± 0.240.71 ± 0.21
Day 1: Cycle 3-0.01 ± 0.22-0.01 ± 0.22
Day 1: Cycle 60.02 ± 0.22-0.00 ± 0.20
Day 1: Cycle 9-0.03 ± 0.27-0.01 ± 0.15
Day 1: Cycle 17-0.02 ± 0.19-0.01 ± 0.23
SecondaryChange From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Score: Visual Analogic Scale (VAS)

EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state utility index (descriptive system) and the EQ-5D-5L Visual Analog Scale. The Visual Analogue Scale is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.

Time frame:
Baseline, Day 1 of each cycle (Cycle 3, Cycle 6, Cycle 9, and Cycle 17)
Reported as:
Mean · centimeter
Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Score: Visual Analogic Scale (VAS)
centimeterPd (Pomalidomide + Dexamethasone)IPd (Isatuximab + Pomalidomide + Dexamethasone)
Baseline65.38 ± 19.3166.62 ± 19.32
Day 1: Cycle 30.26 ± 17.370.92 ± 19.41
Day 1: Cycle 62.49 ± 18.831.19 ± 17.70
Day 1: Cycle 94.42 ± 19.781.96 ± 16.60
Day 1: Cycle 17-1.70 ± 12.39-3.00 ± 12.58

Adverse events

Collected over AE data was collected from the time of first dose of study drug administration up to 30 days following the last administration of study treatment (maximum duration up to 306.6 weeks for Pd arm and 311.0 weeks for IPd arm). Per participant, the deaths were collected up to a maximum duration of approximately 72.38 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pd (Pomalidomide + Dexamethasone)115/153 (75.2%)91/149 (61.1%)139/149 (93.3%)
IPd (Isatuximab + Pomalidomide + Dexamethasone)110/154 (71.4%)112/152 (73.7%)145/152 (95.4%)
Most frequent serious events
Showing 10 of 180
Most frequent serious events
EventPd (Pomalidomide + Dexamethasone)IPd (Isatuximab + Pomalidomide + Dexamethasone)
PneumoniaInfections and infestations31/14935/152
Febrile NeutropeniaBlood and lymphatic system disorders5/14910/152
Disease ProgressionGeneral disorders8/1499/152
BronchitisInfections and infestations1/1497/152
Lower Respiratory Tract InfectionInfections and infestations3/1497/152
Urinary Tract InfectionInfections and infestations2/1497/152
Pathological FractureMusculoskeletal and connective tissue disorders4/1497/152
Acute Kidney InjuryRenal and urinary disorders6/1496/152
Infusion Related ReactionInjury, poisoning and procedural complications1/1496/152
Pneumocystis Jirovecii PneumoniaInfections and infestations5/1494/152
Most frequent other events
Showing 10 of 46
Most frequent other events
EventPd (Pomalidomide + Dexamethasone)IPd (Isatuximab + Pomalidomide + Dexamethasone)
NeutropeniaBlood and lymphatic system disorders52/14977/152
Upper Respiratory Tract InfectionInfections and infestations28/14953/152
Infusion Related ReactionInjury, poisoning and procedural complications1/14952/152
DiarrhoeaGastrointestinal disorders32/14949/152
BronchitisInfections and infestations16/14937/152
FatigueGeneral disorders32/14930/152
ConstipationGastrointestinal disorders30/14927/152
Oedema PeripheralGeneral disorders18/14930/152
AstheniaGeneral disorders29/14923/152
Back PainMusculoskeletal and connective tissue disorders24/14929/152

Baseline characteristics

Analysis was performed on randomized population which included all participants with a signed informed consent and have been allocated a randomization number by the IRT, regardless of whether the participants was treated or not.

Age, Continuous
Age, Continuous(years)Pd (Pomalidomide + Dexamethasone)IPd (Isatuximab + Pomalidomide + Dexamethasone)Total
Mean65.2 ± 9.566.6 ± 9.165.9 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)Pd (Pomalidomide + Dexamethasone)IPd (Isatuximab + Pomalidomide + Dexamethasone)Total
Female8365148
Male7089159
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pd (Pomalidomide + Dexamethasone)IPd (Isatuximab + Pomalidomide + Dexamethasone)Total
American Indian or Alaska Native000
Asian152136
Native Hawaiian or Other Pacific Islander123
Black or African American314
White126118244
More than one race000
Unknown or Not Reported81220
08

Study locations

111 sites
  • BRCR Medical Center Inc. Site Number : 8400002
    Plantation, Florida 33324, United States
  • Dana Farber Site Number : 8400006
    Boston, Massachusetts 02215, United States
  • Investigational Site Number : 0360004
    St Leonards, New South Wales 2065, Australia
  • Investigational Site Number : 0360001
    Waratah, New South Wales 2298, Australia
  • Investigational Site Number : 0360005
    Melbourne, Victoria 3000, Australia
  • Investigational Site Number : 0360002
    Melbourne, Victoria 3004, Australia
  • Investigational Site Number : 0360006
    Richmond, Victoria 3121, Australia
  • Investigational Site Number : 0560003
    Antwerpen, 2060, Belgium
  • Investigational Site Number : 0560002
    Brussel, 1090, Belgium
  • Investigational Site Number : 0560004
    Gent, 9000, Belgium
  • Investigational Site Number : 0560001
    Leuven, 3000, Belgium
  • Investigational Site Number : 1240001
    Montreal, Quebec H1T 2M4, Canada
  • Investigational Site Number : 1240004
    Montreal, Quebec H4A 3J1, Canada
  • Investigational Site Number : 1240005
    Sherbrooke, Quebec J1H 5N4, Canada
  • Investigational Site Number : 2030005
    Brno, 62500, Czechia
  • Investigational Site Number : 2030004
    Hradec Kralove, 50005, Czechia
  • Investigational Site Number : 2030001
    Olomouc, 77900, Czechia
  • Investigational Site Number : 2030002
    Ostrava - Poruba, 70852, Czechia
  • Investigational Site Number : 2030003
    Praha 2, 12808, Czechia
  • Investigational Site Number : 2080002
    Ålborg, 9100, Denmark
  • Investigational Site Number : 2500021
    Bayonne, 64100, France
  • Investigational Site Number : 2500008
    Caen, 14033, France
  • Investigational Site Number : 2500009
    Dijon, 21000, France
  • Investigational Site Number : 2500017
    Grenoble, 38043, France
  • Investigational Site Number : 2500013
    La Roche Sur Yon, 85925, France
  • Investigational Site Number : 2500003
    Lille, 59037, France
  • Investigational Site Number : 2500023
    Limoges, 87042, France
  • Investigational Site Number : 2500019
    Montpellier Cedex, 34295, France
  • Investigational Site Number : 2500002
    Nantes, 44093, France
  • Investigational Site Number : 2500015
    Paris, 75005, France
  • Investigational Site Number : 2500016
    Paris, 75743, France
  • Investigational Site Number : 2500005
    Pessac, 33600, France
  • Investigational Site Number : 2500004
    Pierre Benite, 69495, France
  • Investigational Site Number : 2500007
    POITIERS Cedex, 86021, France
  • Investigational Site Number : 2500025
    Reims, 51092, France
  • Investigational Site Number : 2500014
    Rennes, 35033, France
  • Investigational Site Number : 2500001
    TOULOUSE Cedex 9, 31059, France
  • Investigational Site Number : 2500012
    Tours, 37044, France
  • Investigational Site Number : 2500018
    Vandoeuvre-les-nancy, 54511, France
  • Investigational Site Number : 2760001
    Leipzig, 04103, Germany
  • Investigational Site Number : 3000002
    Athens, 106 76, Greece
  • Investigational Site Number : 3000005
    Athens, 11527, Greece
  • Investigational Site Number : 3000001
    Athens, 11528, Greece
  • Investigational Site Number : 3000004
    Patra, 26504, Greece
  • Investigational Site Number : 3000003
    Thessaloniki, 57010, Greece
  • Investigational Site Number : 3480001
    Budapest, 1083, Hungary
  • Investigational Site Number : 3480003
    Budapest, 1097, Hungary
  • Investigational Site Number : 3480002
    Debrecen, 4032, Hungary
  • Investigational Site Number : 3800001
    Bologna, 40138, Italy
  • Investigational Site Number : 3800010
    Catania, 95123, Italy
  • Investigational Site Number : 3800009
    Firenze, 50134, Italy
  • Investigational Site Number : 3800008
    Genova, 16132, Italy
  • Investigational Site Number : 3800007
    Milano, 20132, Italy
  • Investigational Site Number : 3800002
    Milano, 20133, Italy
  • Investigational Site Number : 3800006
    Padova, 35128, Italy
  • Investigational Site Number : 3800004
    Terni, 05100, Italy
  • Investigational Site Number : 3800003
    Torino, 10126, Italy
  • Investigational Site Number : 3920001
    Nagoya-shi, Aichi 467-8602, Japan
  • Investigational Site Number : 3920005
    Shibukawa-shi, Gunma 377-0280, Japan
  • Investigational Site Number : 3920004
    Sapporo-shi, Hokkaido 060-8543, Japan
  • Investigational Site Number : 3920006
    Kyoto-shi, Kyoto 603-8151, Japan
  • Investigational Site Number : 3920008
    Suwa-shi, Nagano 392-8510, Japan
  • Investigational Site Number : 3920003
    Okayama-shi, Okayama 701-1192, Japan
  • Investigational Site Number : 3920007
    Sunto-gun, Shizuoka 411-8777, Japan
  • Investigational Site Number : 3920002
    Shibuya-ku, Tokyo 150-8935, Japan
  • Investigational Site Number : 4100007
    Hwasun-gun, Jeollanam-do 58128, Korea, Republic of
  • Investigational Site Number : 4100001
    Seoul, Seoul-teukbyeolsi 03080, Korea, Republic of
  • Investigational Site Number : 4100002
    Seoul, Seoul-teukbyeolsi 06351, Korea, Republic of
  • Investigational Site Number : 4100006
    Incheon, 21565, Korea, Republic of
  • Investigational Site Number : 4100005
    Seoul, 06591, Korea, Republic of
  • Investigational Site Number : 5540001
    Takapuna, Auckland 1309, New Zealand
  • Investigational Site Number : 5540004
    Dunedin, Otago 9016, New Zealand
  • Investigational Site Number : 5540003
    Hamilton, Waikato 3204, New Zealand
  • Investigational Site Number : 5540002
    Auckland, 2025, New Zealand
  • Investigational Site Number : 5780001
    Oslo, 0450, Norway
  • Investigational Site Number : 6160003
    Lublin, Lubuskie 20-081, Poland
  • Investigational Site Number : 6160005
    Krakow, Malopolskie 31-501, Poland
  • Investigational Site Number : 6160001
    Warszawa, Mazowieckie 02-776, Poland
  • Investigational Site Number : 6160002
    Chorzow, Slaskie 41-500, Poland
  • Investigational Site Number : 6200004
    Coimbra, 3000-075, Portugal
  • Investigational Site Number : 6200002
    Lisboa, 1070, Portugal
  • Investigational Site Number : 6200001
    Porto, 4200, Portugal
  • Investigational Site Number : 6430004
    Moscow, 125167, Russian Federation
  • Investigational Site Number : 6430001
    Moscow, 125284, Russian Federation
  • Investigational Site Number : 6430002
    Moscow, 129301, Russian Federation
  • Investigational Site Number : 7030001
    Bratislava, 83310, Slovakia
  • Investigational Site Number : 7240005
    Santiago de Compostela, A Coruña [La Coruña] 15706, Spain
  • Investigational Site Number : 7240001
    Barcelona, Barcelona [Barcelona] 08035, Spain
  • Investigational Site Number : 7240006
    Santander, Cantabria 39008, Spain
  • Investigational Site Number : 7240002
    Pamplona, Navarra 31008, Spain
  • Investigational Site Number : 7240003
    Madrid, 28006, Spain
  • Investigational Site Number : 7240004
    Salamanca, 37007, Spain
  • Investigational Site Number : 7520004
    Luleå, 97180, Sweden
  • Investigational Site Number : 7520005
    Uddevalla, 451 80, Sweden
  • Investigational Site Number : 1580004
    Kaohsiung, 833, Taiwan
  • Investigational Site Number : 1580002
    Taichung, 40447, Taiwan
  • Investigational Site Number : 1580001
    Taipei, 100, Taiwan
  • Investigational Site Number : 1580003
    Taoyuan, 333, Taiwan
  • Investigational Site Number : 7920001
    Ankara, 06620, Turkey
  • Investigational Site Number : 7920002
    Antalya, 07050, Turkey

Showing the first 100 of 111 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Mace S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14. Erratum In: Lancet. 2019 Dec 7;394(10214):2072. doi: 10.1016/S0140-6736(19)32944-7. PubMed 31735560 ↗
  • Richardson PG, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Malinge L, Dubin F, van de Velde H, Anderson KC. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol. 2022 Mar;23(3):416-427. doi: 10.1016/S1470-2045(22)00019-5. Epub 2022 Feb 10. Erratum In: Lancet Oncol. 2022 Apr;23(4):e161. doi: 10.1016/S1470-2045(22)00131-0. Lancet Oncol. 2022 Sep;23(9):e404. doi: 10.1016/S1470-2045(22)00493-4. PubMed 35151415 ↗
  • Sunami K, Ikeda T, Huang SY, Wang MC, Koh Y, Min CK, Yeh SP, Matsumoto M, Uchiyama M, Iyama S, Shimazaki C, Lee JH, Kim K, Kaneko H, Kim JS, Lin TL, Campana F, Tada K, Iida S, Suzuki K; ICARIA-MM study group. Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis. Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):e751-e761. doi: 10.1016/j.clml.2022.04.005. Epub 2022 Apr 8. PubMed 35641409 ↗
  • Wilmoth J, Colson K, Dubin F, Kellam C. Isatuximab: Nursing Considerations for Use in the Treatment of Multiple Myeloma. Clin J Oncol Nurs. 2021 Dec 1;25(6):706-712. doi: 10.1188/21.CJON.706-712. PubMed 34800109 ↗
  • Bringhen S, Pour L, Vorobyev V, Vural F, Warzocha K, Benboubker L, Koh Y, Maisnar V, Karlin L, Pavic M, Campana F, Le Guennec S, Menas F, van de Velde H, Richardson PG. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. Leuk Res. 2021 May;104:106576. doi: 10.1016/j.leukres.2021.106576. Epub 2021 Mar 29. PubMed 33839618 ↗
  • Schjesvold FH, Richardson PG, Facon T, Alegre A, Spencer A, Jurczyszyn A, Sunami K, Frenzel L, Min CK, Guillonneau S, Lin PL, Le-Guennec S, Campana F, van de Velde H, Bensfia S, Bringhen S. Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Haematologica. 2021 Apr 1;106(4):1182-1187. doi: 10.3324/haematol.2020.253450. No abstract available. PubMed 32586908 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Nov 2018, 23 months.

Results were first posted in Dec 2019, 1 year after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 23 months is below that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2016
First posted
Dec 13, 2016
StartActual
Dec 22, 2016
Primary completionActual
Nov 22, 2018
CompletionActual
Nov 1, 2023
Results first posted
Dec 6, 2019
Last update
Jan 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02990338
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 13, 2016
Start date
Dec 22, 2016
Primary completion
Nov 22, 2018
Completion
Nov 1, 2023
Results posted
Dec 6, 2019
Last update
Jan 17, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Isatuximab

Start the discussion